CLINICAL EVIDENCE
REGENPRP™-HA COMBINATION FOR KNEE OA: RIGLET 2026
The RegenPRP™-HA combination prepared with Cellular Matrix demonstrated significant clinical benefit and a favorable safety profile in patients with moderate knee osteoarthritis compared with a single injection of crosslinked hyaluronic acid (Synvisc-One®).
50.6% of patients achieved an acceptable symptom state for pain at 6 months
compared with 33.3% following treatment with crosslinked hyaluronic acid alone.
Clinical Evidence
A prospective, multicenter, randomized controlled trial evaluated the efficacy and safety of a single injection of RegenPRP™-HA prepared with Cellular Matrix versus a single injection of Synvisc-One® in patients with symptomatic moderate knee osteoarthritis. Follow-up assessments were performed at 1, 3 and 6 months.
- Number of patients: 156 (81 PRP-HA; 75 HA)
- Mean age: 59.6 years
- Kellgren-Lawrence grade II and III knee osteoarthritis
- Single intra-articular injection under ultrasound guidance
RESULTS
- Significant improvement in pain and function was observed in both treatment groups during follow-up.
- PRP-HA demonstrated a significantly greater improvement in WOMAC pain on walking at 6 months compared with crosslinked HA alone (p=0.04).
- More patients achieved an acceptable symptom state for pain (PASS criterion) at 6 months with PRP-HA than with crosslinked HA alone (50.6% vs 33.3%, p=0.03).
- The incidence of adverse events was low and comparable between groups (7.4% vs 5.3%). Most events consisted of transient post-injection pain or swelling.
PASS Responders at 6 Months (%)
% Responders
-
RegenPRP™-HA 50.6%
-
Synvisc-One® 33.3%
CONCLUSION
This randomized controlled trial demonstrated that a single injection of RegenPRP™-HA prepared with Cellular Matrix is a safe and effective treatment option for patients with moderate knee osteoarthritis, providing significant improvement in pain and a higher proportion of patients achieving an acceptable symptom state at 6 months compared with crosslinked hyaluronic acid alone.